Why the study?
Does the combined ETA/ETB receptor antagonist bosentan reduce vascular hypertrophy in DOCA-salt-hypertensive rats?
Does the combined ETA/ETB receptor antagonist bosentan reduce vascular hypertrophy in DOCA-salt-hypertensive rats?
ET-1 gene overexpression in blood vessels accentuates vascular hypertrophy in DOCA-salt-induced hypertension, an effect that can be mitigated by endothelin receptor antagonism.
Answers are grounded in this paper and cite their sources.
Supports ET-1 role in excess vascular hypertrophy in this rat model; leaves open whether endothelin antagonism prevents remodeling in human hypertension.
Endothelin (ET)-1 is a potent vasoconstrictor peptide which is also endowed with hypertrophic and mitogenic properties. Enhanced ET-1 gene expression in blood vessels of rats with hypertension induced by deoxycorticosterone acetate (DOCA)-salt has been previously demonstrated. The objective of this study was: (1) to investigate the individual effects of salt and DOCA, and of the development of hypertension in DOCA-salt-hypertensive rats, on ET-1 gene expression in blood vessels; and (2) to correlate the presence of enhanced ET expression and the severity of vascular hypertrophy. By providing salt and/or DOCA to rats which were or were not unilaterally nephrectomized, groups of rats with variable degrees of blood pressure elevation were generated. Increased abundance of ET-1 mRNA and a greater content of immunoreactive ET-1 were found with progression of hypertension in aorta and the mesenteric arterial bed only in unilaterally nephrectomized DOCA-salt-treated rats (DOCA-salt-hypertensive rats). Vascular expression of ET-1 was not enhanced in other DOCA-or salt-treated rats, even when blood pressure rose to a mean systolic pressure of 180 mm Hg. The wet weight of aorta and the mesenteric arterial bed, the media thickness, the media cross-sectional area, and the media-to-lumen ratio of mesenteric small arteries of all groups of rats exhibited a close correlation with systolic blood pressure. In DOCA-salt-hypertensive rats after 5 weeks, in which overexpression of ET-1 was maximal, the vascular morphometric parameters were excessive for the level of systolic blood pressure. However, in DOCA-salt-hypertensive rats treated with the combined ETA/ETBET receptor antagonist bosentan, vascular morphometry correlated closely with blood pressure, even though blood pressure was only slightly lower than than of untreated DOCA-salt-hypertensive rats. These data support the hypothesis that ET-1 gene overexpression in blood vessels may accentuate vascular hypertrophy in some forms of hypertension.
No takes yet. Share an insight, caveat, or question.
Schiffrin et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: